Verastem Inc. (VSTM)
Verastem Stock Rises Nearly 8% on Strong Q4 & 2025 Preliminary Results
VSTM shares rise nearly 8% after the release of preliminary fourth-quarter 2025 and full-year 2025 sales numbers, driven by Avmapki Fakzynja Co-pack.
Verastem: Downgrading To Buy Based On RAMP-203 Setback In Targeting KRAS G12C NSCLC
Verastem, Inc. is downgraded from Strong Buy" to Buy following discontinuation of its RAMP-203 G12C NSCLC study. VSTM pivots focus to VS-7375, an oral KRAS G12D "ON/OFF" inhibitor, with promising early efficacy and safety data in KRAS G12D NSCLC patients. Upcoming interim phase 1/2a U.S. data for VS-7375 in KRAS G12D solid tumors, expected 1H 2026, is a major catalyst.
Verastem, Inc. (VSTM) Q3 2025 Earnings Call Transcript
Verastem, Inc. ( VSTM ) Q3 2025 Earnings Call November 4, 2025 8:00 AM EST Company Participants Julissa Viana - Vice President of Corporate Communications & Investor Relations Daniel Paterson - President, CEO & Director Matthew Ros - Chief Operating Officer Michael Crowther - Chief Commercial & Strategy Officer Daniel Calkins - Chief Financial Officer Conference Call Participants Michael Schmidt - Guggenheim Securities, LLC, Research Division Justin Zelin - BTIG, LLC, Research Division Xun Lee - H.C. Wainwright & Co, LLC, Research Division Yuan Zhi - B.
Verastem (VSTM) Reports Q3 Loss, Tops Revenue Estimates
Verastem (VSTM) came out with a quarterly loss of $1.35 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to a loss of $0.6 per share a year ago.
Verastem (VSTM) Upgraded to Buy: Here's Why
Verastem (VSTM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Are You Looking for a Top Momentum Pick? Why Verastem (VSTM) is a Great Choice
Does Verastem (VSTM) have what it takes to be a top stock pick for momentum investors? Let's find out.
Verastem, Inc. (VSTM) Q2 2025 Earnings Call Transcript
Verastem, Inc. (NASDAQ:VSTM ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Daniel Calkins - Chief Financial Officer Daniel W. Paterson - President, CEO & Director Julissa Viana - Vice President of Corporate Communications & Investor Relations Matthew E.
Verastem (VSTM) Reports Q2 Loss, Misses Revenue Estimates
Verastem (VSTM) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to a loss of $0.31 per share a year ago.
Earnings Preview: Verastem (VSTM) Q2 Earnings Expected to Decline
Verastem (VSTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Verastem: The Market Is Ignoring The Progress
FDA approval of AVMAPKI FAKZYNJA CO-PACK marks a transformative milestone, positioning Verastem as a commercial-stage leader in KRAS-mutant LGSOC treatment. Verastem's strong cash position and promising pipeline, including VS-7375 for KRAS G12D, offer significant upside with multiple near-term catalysts ahead. Risks include slow commercial uptake, pipeline uncertainty, and potential future dilution, but current valuation under $5 presents an attractive entry point.
Verastem: Approval Secured, Moving On To PDAC And KRAS G12D-Related Cancers
Recent pipeline updates highlight promising new product candidates advancing to late-stage trials, strengthening my confidence in future growth. The company maintains a solid financial position, with strong cash reserves and prudent expense management supporting ongoing R&D initiatives. Key strengths include a diversified portfolio and robust clinical data, though regulatory risks and competition remain notable challenges.
VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval
Verastem Oncology jumps 22% on FDA nod for Avmapki Fakzynja, the first approved KRAS-mutant LGSOC therapy, with strong early data in a pancreatic cancer study.
